Status:
COMPLETED
Deep Endoscopic Remission Assessed by a Surrogate Biomarker in Patients With Inflammatory Bowel Disease
Lead Sponsor:
Herlev Hospital
Collaborating Sponsors:
University Hospital of North Norway
Hvidovre University Hospital
Conditions:
Inflammatory Bowel Disease
Crohn Disease
Eligibility:
All Genders
Up to 67 years
Brief Summary
We hypothesize that the number of needed endoscopic procedure performed at IBD patients (adult and children), can be reduced by using an individualized algorithm of symptoms, blood and faecal biomarke...
Detailed Description
Deep remission: The treatment goal in patiens with IBD is to achieve deep remission before drug withdrawal to avoid relapse. In order to evaluate the healing of mucosa, it is currently necessary to ca...
Eligibility Criteria
Inclusion
- Patients scheduled for endoscopy
- Age 0 - 67 years
- Intestinal infections ruled out by stool sample analysis for pathogenic bacteria, parasites and Clostridium difficile
- CMV ruled out
- Fluent in Danish
Exclusion
- American Society of Anesthesiologists (ASA) score III or above
- Patients who are alcohol or drug abusers
Key Trial Info
Start Date :
November 1 2013
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 28 2018
Estimated Enrollment :
157 Patients enrolled
Trial Details
Trial ID
NCT01861288
Start Date
November 1 2013
End Date
February 28 2018
Last Update
February 27 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Katrine Carlsen
Herlev, Denmark, 2730